Table 2.
Cox regression analysis of the GESBN models and clinical variables in the training cohort.
| Overall survival | ||||
|---|---|---|---|---|
| Variables | Univariate analysis | Multivariate analysis | ||
| HR (95% CI) | P value | HR (95% CI) | P value | |
| PR status | 0.552 (0.363–0.838) | 0.005 | 0.660 (0.398–1.094) | 0.107 |
| PES | 0.644 (0.403–1.029) | 0.066 | 0.649 (0.405–1.040) | 0.073 |
| Stage | 1.006 (0.656–1.543) | 0.979 | 1.214 (0.673–2.192) | 0.519 |
| Risk score | 2.719 (1.663–4.447) | <0.001 | 2.289 (1.253–4.180) | 0.007 |
|
| ||||
| Progression-free survival | ||||
| PR status | 0.598 (0.420–0.853) | 0.004 | 0.807 (0.531–1.228) | 0.317 |
| PES | 0.600 (0.395–0.912) | 0.017 | 0.657 (0.424–1.016) | 0.059 |
| Stage | 0.750 (0.517–1.088) | 0.129 | 1.006 (0.604–1.674) | 0.983 |
| Risk score | 2.710 (1.920–3.824) | <0.001 | 2.624 (1.757–3.919) | <0.001 |
abrAbbreviations: GESBN, gene expression signature-based nomogram; HR, hazard ratio; 95% CI, 95% confidence interval; PR status, progesterone receptor status; PES, prior endocrine sensitivity.